
## **Product Data Sheet**

## FITC anti-mouse IFN-γ

Catalog # / Size:	3129025 / 25 μg 3129030 / 100 μg
Clone:	XMG1.2
Isotype:	Rat IgG1, к
Immunogen:	<i>E. coli</i> -expressed, recombinant mouse IFN-γ
<b>Reactivity:</b>	Mouse
Preparation:	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration:	0.5




C57BL/6 mouse splenocytes were stimulated with PMA + lonomycin for 6 hours (in the presence of monensin), stained with CD3 APC, fixed, permeabilized, and then stained with IFN- $\gamma$  (clone XMG1.2) FITC (top) or rat IgG1,  $\kappa$  FITC isotype control (bo

## **Applications:**

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is $\leq 1.0$ microg per 10 <sup>6</sup> cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

 Application Notes:
 ELISA<sup>1-4,11,14</sup> or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard.
 ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA

or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF<sup>™</sup> purified antibody



For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com is suggested for ELISPOT capture (Cat. No. 505812).

**Flow Cytometry**<sup>7,8,12,13,16</sup>: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γproducing cells within mixed cell populations.

**Neutralization**<sup>1-3,9,10</sup>: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN- $\gamma$ . The LEAF<sup>TM</sup> purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN- $\gamma$  bioactivity *in vivo* and *in vitro* (Cat. No. 505812). For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF<sup>TM</sup> purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF<sup>TM</sup> purified antibodies (Endotoxin <0.01 EU/microg).

Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections<sup>6,22,23</sup>, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max<sup>™</sup> Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References:	<ol> <li>Abrams J, <i>et al.</i> 1992. <i>Immunol. Rev.</i> 127:5. (ELISA, Neut)</li> <li>Sander B, <i>et al.</i> 1993. <i>J. Immunol. Meth.</i> 166:201. (ELISA, Neut)</li> <li>Abrams J, <i>et al.</i> 1995. <i>Curr. Prot. Immunol.</i> John Wiley and Sons, New York. Unit</li> <li>(ELISA, Neut)</li> <li>Yang X, <i>et al.</i> 1993. <i>J. Immunoassay</i> 14:129. (ELISA)</li> <li>Klinman D, <i>et al.</i> 1994. <i>Curr. Prot. Immunol.</i> John Wiley and Sons, New York. Unit</li> <li>(ELISPOT)</li> <li>Sander B, <i>et al.</i> 1991. <i>Immunol. Rev.</i> 119:65. (IHC)</li> <li>Ferrick D, <i>et al.</i> 1995. <i>Nature</i> 373:255. (FC)</li> <li>Ko SY, <i>et al.</i> 2005. <i>J. Immunol.</i> 175:3309. (FC) PubMed</li> <li>Peterson KE, <i>et al.</i> 2000. <i>J. Virol.</i> 74:5363. (Neut)</li> <li>DeKrey GK, <i>et al.</i> 1998. <i>Infect. Immunol.</i> 66:827. (Neut)</li> <li>Dragalov I, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:5366. (FC)</li> <li>Lawson BR, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5358. (ELISA)</li> <li>Lee JW, <i>et al.</i> 2007. <i>J. Immunol.</i> 179:5358. (ELISA)</li> <li>Montfort M, <i>et al.</i> 2008. <i>J. Immunol.</i> 180:2855. (FC) PubMed</li> <li>Haring JS, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4516. PubMed</li> <li>Haring JS, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4516. PubMed</li> <li>Tonkin DR, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4516. PubMed</li> <li>Tonkin DR, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4516. PubMed</li> </ol>
	17. Jordan JM, <i>et al.</i> 2008. <i>Infect Immun.</i> 76:3717. <u>PubMed</u> 18. Tonkin DR, <i>et al.</i> 2008. <i>J. Immunol.</i> 181:4516. <u>PubMed</u>
	20. Cui Y, <i>et al.</i> 2009. <i>Invest. Ophth. Vis. Sci.</i> 50:5811. (FC) <u>PubMed</u> 21. Mykkanen OT, <i>et al.</i> 2014. <i>PLoS One.</i> 9:114790. <u>PubMed</u> 22. Yokogawa M, <i>et al.</i> 2013. <i>Mol. Carcinog.</i> 52:760. (IHC)
	23. Mottram PL, <i>et al.</i> 1998. <i>J Immunol</i> . 161:602. (IHC)

**Description:** IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com Antigen1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press, SanReferences:Diego.

2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.

3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571